Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

Back

ESC Professional Premium Access

Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

Session: Biomarkers to guide the treatment of heart failure: where are we going?

Topic: Pharmacotherapy

Speaker: Doctor Y. Yu (Leuven, BE)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Yuling Yu

Leuven (Belgium)

0 follower

4 more presentations in this session

State-of-the-art lecture on biomarkers to guide the treatment of heart failure: where are we going?

Speaker: Professor J. Januzzi (Boston, US)

Access

Slides

Video

Outcomes and effects of sacubitril/valsartan according to NT-proBNP level in patients with heart failure: a patient-level pooled analysis of the PARADIGM-HF and PARAGON-HF trials

Speaker: Doctor T. Kondo (Glasgow, GB)

Heart failure and renal outcomes in patient treated with GLP1 agonists.

Speaker: Doctor N. del-Cuerpo-Salinas (Sant Joan d'Alacant, ES)

Liver function tests in patients receiving high-intensity care after hospital admission for acute heart failure: the STRONG-HF trial

Speaker: Doctor P. Myhre (Nordbyhagen, NO)

Access the full session

Biomarkers to guide the treatment of heart failure: where are we going?

Speakers: Doctor Y. Yu, Professor J. Januzzi, Doctor T. Kondo, Doctor N. del-Cuerpo-Salinas, Doctor P. Myhre

Access

Video

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources